Table 1.
Amino acid sequence of de novo designed 3SCC analogues.[a]
| Peptide | Sequence | ||||||
|---|---|---|---|---|---|---|---|
| abcdefg | abcdefg | abcdefg | abcdefg | abcdefg | |||
| CoilSer | Ac-E | WEALEKK | LAALESK | LQALEKK | LEALEHG | −NH2 | |
| Baby | Ac-G | LKALEEK | LKALEEK | LKALEEK | G-NH2 | ||
| TRI | Ac-G | LKALEEK | LKALEEK | LKALEEK | LKALEEK | G-NH2 | |
| Grand | Ac-G | LKALEEK | LKALEEK | LKALEEK | LKALEEK | LKALEEK | G-NH2 |
Leucine residues at the “a” or “d” positions are mutated to metal-binding residues such as cysteine, penicillamine, or histidine. Mutation of Leu residues to Cys and His at the 9th and 23rd positions, respectively, is designated as TRIL9CL23H.